ASCO 2024 | Phase I/II study of AdAPT-001 plus an ICI for patients with immune refractory cancers
Anthony Paul Conley, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a multicenter Phase II trial (NCT04673942) evaluating AdAPT-001, an oncolytic adenovirus armed with a “TGF-β trap,” +/- a checkpoint inhibitor (CI) in resistant patients, some previously CI-failed. 36 patients received AdAPT-001, with or without a CI, showing manageable adverse events. The combination therapy demonstrated a high objective response rate (ORR) of 29.1% and a clinical benefit rate of 62.5%, suggesting potential efficacy in refractory tumors, particularly in cutaneous sarcomas. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
